Drug Trial Radar · NCT05466890
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Sep 15, 2022
Primary completion
Feb 10, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Palatin Technologies, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).
Conditions
- Ulcerative Colitis
- Ulcerative Colitis Acute
- Ulcerative
- Ulcerative Colitis Flare
Interventions
PL8177 PlaceboDrug
Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
PL8177Drug
Approximately 3/4 of randomized patients will receive active PL8177.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of PL8177 compared to placebo in patients with active UC.Time frame: Baseline through Study Completion (Week 12).
- To compare the proportion of subjects achieving Mayo Endoscopic Subscore of ≤ 1 point (0 or 1) between PL8177 and placebo after 8 weeks of treatment.Time frame: Time Frame: Mayo Endoscopic Subscore will be evaluated at Week 8.
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Del Sol Research Management, LLC
Tucson, Arizona
Gastro Care Institute
Lancaster, California
Valiance Clinical Research
Tarzana, California
Advanced Research LLC
Coral Springs, Florida
IHS Health Research/Gastro Health
Kissimmee, Florida
Orlando Health, Inc.
Orlando, Florida
Kansas Gastroenterology
Wichita, Kansas
Gastroenterology Clinic of Acadiana
Lafayette, Louisiana
Delta Research Partners
Monroe, Louisiana
Allied Health Clinical Research Organization, LLC - Englewood
Englewood, New Jersey
Allied Digestive Health LLC
Freehold, New Jersey
Allied Health Clinical Research Organization, LLC
Jackson, New Jersey
Weill Cornell Medicine - Jill Roberts Center for Inflammatory Bowel Disease
New York, New York
UPMC Presbyterian
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.